These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33126941)

  • 1. Strengthened capacity of India´s bedaquiline Conditional Access Programme for introducing new drugs and regimens.
    Sachdeva KS; Arora N; Solanki R; Singla R; Sarin R; Bhatnagar A; Khanna A; Atahavale A; Shridhar R; Barua SR; Parmar M; Farooq SI; Ramachandran R; Alavadi U; Swamickan R; Tonsing J; Patel Y; Singla N
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1067-1072. PubMed ID: 33126941
    [No Abstract]   [Full Text] [Related]  

  • 2. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
    Sarin R; Singla N; Vohra V; Singla R; Puri MM; Munjal S; Khalid UK; Myneedu VP; Kumar Verma A; Mathuria KK
    Indian J Tuberc; 2019 Jan; 66(1):209-213. PubMed ID: 30878071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India.
    Das M; Dalal A; Laxmeshwar C; Ravi S; Mamnoon F; Meneguim AC; Paryani R; Mathur T; Singh P; Mansoor H; Kalon S; Hossain FN; Lachenal N; Coutisson S; Ferlazzo G; Isaakidis P
    Clin Infect Dis; 2021 Nov; 73(9):e3496-e3504. PubMed ID: 33079176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.
    Salhotra VS; Sachdeva KS; Kshirsagar N; Parmar M; Ramachandran R; Padmapriyadarsini C; Patel Y; Mehandru L; Jaju J; Ponnuraja C; Gupta M; Kalaiselvan V; Shamim A; Khaparde S; Swaminathan S;
    Indian J Tuberc; 2020 Jan; 67(1):29-37. PubMed ID: 32192613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introducing bedaquiline: experiences from the Challenge TB Project.
    Edwards CG; Wares DF; Dravniece G; Gebhard A; Tiemersma E; van der Grinten E; Gidado M; van Weezenbeek K
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1046-1053. PubMed ID: 33126937
    [No Abstract]   [Full Text] [Related]  

  • 6. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.
    Ionescu AM; Mpobela Agnarson A; Kambili C; Metz L; Kfoury J; Wang S; Williams A; Singh V; Thomas A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):677-689. PubMed ID: 30073886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis.
    Sarin R; Vohra V; Singla N; Singla R; Puri MM; Munjal SK; Khalid UK; Myneedu VP; Verma A; Mathuria KK
    Indian J Tuberc; 2019 Jan; 66(1):184-188. PubMed ID: 30878066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety.
    Gao JT; Du J; Wu GH; Pei Y; Gao MQ; Martinez L; Fan L; Chen W; Xie L; Chen Y; Wang H; Jin L; Li GB; Zong PL; Xiong Y; Wu QH; Li MW; Yan XF; Miao YF; Cai QS; Li XJ; Bai DP; Geng SJ; Yang GL; Tang PJ; Zeng Y; Chen XH; Li TX; Cai C; Zhou Y; Zhuo M; Wang JY; Guan WL; Xu L; Shi JC; Shu W; Cheng LL; Teng F; Ning YJ; Xie SH; Sun YX; Zhang LJ; Liu YH
    Infect Dis Poverty; 2021 Mar; 10(1):32. PubMed ID: 33736710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishing the Safety and Efficacy of Bedaquiline-Containing Regimen for the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Jihwaprani MC; Sun Y; Rizky WC; Sula I; Saquib N
    Pulm Med; 2024; 2024():5542658. PubMed ID: 39157539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Bedaquiline Donation Program: progress and lessons learned after 4 years of implementation.
    Rutta E; Kambili C; Mukadi Y
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1039-1045. PubMed ID: 33126936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Setting up pharmacovigilance based on available endTB Project data for bedaquiline.
    Lachenal N; Hewison C; Mitnick C; Lomtadze N; Coutisson S; Osso E; Ahmed S; Leblanc G; Islam S; Atshemyan H; Nair P; Kholikulov B; Aiylchiev S; Zarli K; Adnan S; Krisnanda A; Padayachee S; Stambekova A; Sahabutdinova Y; de Guadalupe S; Moreno P; Kumsa A; Reshid A; Makaka J; Abebe S; Melikyan N; Seung KJ; Khan U; Khan P; Huerga H; Rich M; Varaine F
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1087-1094. PubMed ID: 33126944
    [No Abstract]   [Full Text] [Related]  

  • 12. New TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, India.
    Das M; Mamnoon F; Mansoor H; Meneguim AC; Singh P; Shah I; Ravi S; Kalon S; Hossain FN; Ferlazzo G; Isaakidis P; Furin J; Acharya S; Thakur HP
    Int J Tuberc Lung Dis; 2020 Dec; 24(12):1265-1271. PubMed ID: 33317670
    [No Abstract]   [Full Text] [Related]  

  • 13. Overcoming barriers to the access and uptake of newer drugs for multidrug-resistant TB.
    Zabsonre I; Thi SS; Cox V
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1054-1057. PubMed ID: 33126938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction and scaling up of new drugs for drug-resistant TB: experiences from the Americas.
    Bernal O; Lopez R; Montoro E; Avedillo P; Westby K; Ghidinelli M
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1058-1062. PubMed ID: 33126939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction of bedaquiline for the treatment of drug-resistant TB in the Philippines.
    Santiago MR; Garfin AMC; Balanag VM
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1063-1066. PubMed ID: 33126940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol.
    Padmapriyadarsini C; Devaleenal B; Ponnuraja C; Ramraj B; Singla R; Parmar M; Mattoo S; Mandal S
    BMJ Open; 2022 Aug; 12(8):e058606. PubMed ID: 36038181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis.
    Ndjeka N; Conradie F; Schnippel K; Hughes J; Bantubani N; Ferreira H; Maartens G; Mametja D; Meintjes G; Padanilam X; Variava E; Pym A; Pillay Y
    Int J Tuberc Lung Dis; 2015 Aug; 19(8):979-85. PubMed ID: 26162365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis in China.
    Han X; Chen X; Sha W; Zhang X; Qiu L; Wang J; Wu G; Yao L; Lv Y; Zhang X; Zhou J; Tang S; Chu N
    Int J Tuberc Lung Dis; 2020 Aug; 24(8):789-794. PubMed ID: 32912383
    [No Abstract]   [Full Text] [Related]  

  • 19. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
    Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the all-oral bedaquiline-containing regimen as treatment for pediatric multidrug/rifampicin-resistant tuberculosis: a multicenter, retrospective, cohort study.
    Sun WW; Yang M; Chen XH; Fan LC; Wu HY; Zhang SJ; Chen Y; Fan L
    Expert Rev Anti Infect Ther; 2024 Apr; 22(4):219-227. PubMed ID: 37982155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.